The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) harboring select FGFR mutations or fusions: Phase 1 first-in-human study.
 
Antoni Vilaseca
No Relationships to Disclose
 
Félix Guerrero
Honoraria - Janssen; Pfizer
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Janssen; Pfizer
Speakers' Bureau - Combat Medical; Janssen
Research Funding - Combat Medical
Travel, Accommodations, Expenses - Ipsen; Pfizer
 
Daniel Zainfeld
No Relationships to Disclose
 
Neal D. Shore
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Sanofi; CG Oncology; CG Oncology; Clarity Pharmaceuticals; Clovis Oncology; Dendreon; Exact Imaging; Exact Sciences; FerGene; Ferring; Foundation Medicine; Genesis Cancer Care; Genzyme; Genzyme; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Myovant Sciences; Myriad Genetics; Nymox; Pacific Edge Biotechnology; Peerview; Pfizer; Phosphorus; Photocure; Propella Therapeutics; Sanofi; Sema4; Sesen Bio; Speciality Networks; Telix Pharmaceuticals; Tempus; Tolmar; Urogen pharma; Vaxiion
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Foundation Medicine; Guardant Health; Janssen; Merck; Pfizer
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; Seagen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow
Expert Testimony - Ferring
Other Relationship - Alessa Therapeutics; Photocure
 
Oscar Rodriguez Faba
No Relationships to Disclose
 
Richard P. Meijer
No Relationships to Disclose
 
Alfred Alfred Witjes
Honoraria - Astellas Pharma; AstraZeneca; Beigene; Bristol-Myers Squibb/Pfizer; Ferring; Janssen; MSD; Nucleix
Consulting or Advisory Role - Asieris Pharmaceuticals; AstraZeneca; BeiGene; Bristol-Myers Squibb; Ferring; Janssen Oncology; MSD; oncodiag; photocure; Urogen pharma
 
Autumn Jackson McRee
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson and Johnson
Research Funding - AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Boston Biomedical (Inst); Inovio Pharmaceuticals (Inst); Merck (Inst); Novartis (Inst); Rgenix (Inst); Takeda (Inst)
 
Anna Kalota
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson
 
Nicole L. Stone
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson
 
Josh David Lauring
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
Consulting or Advisory Role - Galderma (I); Novartis (I); Regeneron (I)
Speakers' Bureau - Abbvie (I); Galderma (I); Pfizer (I)
Patents, Royalties, Other Intellectual Property - I intermittently receive royalty payments for cell lines created in my laboratory which are licensed for commercial sale to Horizon Discovery, Ltd by Johns Hopkins University.
Travel, Accommodations, Expenses - Abbvie (I); Galderma (I)
 
Wei Zhu
Employment - Johnson & Johnson
 
Neil Beeharry
Employment - Janssen Oncology
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Patents, Royalties, Other Intellectual Property - Apilimod compositions and methods for using same in the treatment of renal cancer: The present disclosure relates to methods for treating renal cancer with apilimod and related compositions and methods.; Apilimod compositions and methods for using same: The present invention relates to methods for treating cancer with apilimod and related compositions and methods.; METHOD FOR TREATING CANCER USING HSP90 INHIBITORS: The disclosure also provides compositions and methods related to combination therapy with HSP90 inhibitors and BCL-2 pathway inhibitors for treating cancer. The disclosure also provides compositions and m
Travel, Accommodations, Expenses - Janssen Research & Development
 
Lang A O'Dondi
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson
 
Gautam Jayram
Stock and Other Ownership Interests - KDx Diagnostics
Honoraria - AstraZeneca; Blue Earth Diagnostics; Janssen; Merck; Photocure
Consulting or Advisory Role - Bristol Myers Squibb Foundation; KDx Diagnostics; Merck; Photocure
Research Funding - AstraZeneca; Blue Earth Diagnostics; Bristol Myers Squibb Foundation; Janssen; Merck
Travel, Accommodations, Expenses - AstraZeneca; Blue Earth Diagnostics; Janssen; Merck; Photocure